GlaxoSmithKline: FDA panel backs Votrient for kidney cancer but hurdles remain - Trading Markets (press release) PDF Print
Trading Markets (press release)Following the panel voting 10-0 in favor of Votrient (pazopanib; GlaxoSmithKline) in the treatment of advanced renal cell carcinoma (RCC), the FDA has until

... read more

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.